NIROGI, Ramakrishna,罗摩克里希纳．尼罗吉,羅摩克里希納．尼羅吉,MOHAMMED, Abdul Rasheed,阿卜杜勒．拉希德．穆罕默德,SHINDE, Anil Karbhari,阿尼尔．卡巴里．欣德,阿尼爾．卡巴里．欣德,GAGGINAPALLY, Shankar Reddy,尚卡尔．雷迪．加吉那帕利,尚卡爾．雷迪．加吉那帕利,JASTI, V,罗摩克里希纳.尼罗吉,羅摩克里希納.尼羅吉,阿卜杜勒.拉希德.穆罕默德,阿尼尔.卡巴里.欣德,阿尼爾.卡巴里.欣德,尚卡尔.雷迪.加吉那帕利,尚卡爾.雷迪.加吉那帕利
申请号：
MOJ003229
公开号：
MOJ003229B
申请日:
2018.08.14
申请国别(地区):
MO
年份:
2018
代理人:
摘要：
The present invention relates to the new indazole compounds of formula (I), including its stereoisomer and its officinal salt, and wherein R1 is alkyl or cycloalkyl； Pharmaceutical composition the invention further relates to the method for preparing such compound and comprising such compound. The compound of the present invention can treat a variety of diseases relevant to (5-HT4) receptor stimulating agent of 5-HT 4 with what.本發明涉及式(I)的新吲唑化合物，包括其立體異構體及其可藥用鹽，其中R1是烷基或環烷基；本發明還涉及製備這樣的化合物的方法和包含這樣的化合物的藥物組合物。本發明的化合物可用於治療與5‑羥基‑色胺4(5‑HT4)受體激動劑相關的多種疾病。
